238 results on '"Anes, Elsa"'
Search Results
2. Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial N-Alkyl Nitrobenzamides
3. Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold
4. Cystatin F Depletion in Mycobacterium tuberculosis-Infected Macrophages Improves Cathepsin C/Granzyme B-driven Cytotoxic Effects on HIV-Infected Cells during Coinfection.
5. Editorial: Immune responses to MTB infection in people living with HIV.
6. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis
7. Cystatin F Depletion in Mycobacterium tuberculosis -Infected Macrophages Improves Cathepsin C/Granzyme B-Driven Cytotoxic Effects on HIV-Infected Cells during Coinfection.
8. Role of Type I Interferons during Mycobacterium tuberculosis and HIV Infections.
9. Ethambutol and Meropenem/Clavulanate Synergy Promotes Enhanced Extracellular and Intracellular Killing ofMycobacterium tuberculosis
10. Human immunodeficiency virus transmission—Mechanisms underlying the cell‐to‐cell spread of human immunodeficiency virus
11. Unravelling the triad of neuroinvasion, neurodissemination, and neuroinflammation of human immunodeficiency virus type 1 in the central nervous system.
12. Modulation of Cystatin F in Human Macrophages Impacts Cathepsin-Driven Killing of Multidrug-Resistant Mycobacterium tuberculosis
13. ESAT-6 a Major Virulence Factor of Mycobacterium tuberculosis and a Target for New Therapeutic Interventions
14. ESAT-6 a Major Virulence Factor of Mycobacterium tuberculosis
15. Immunomodulating microRNAs of mycobacterial infections
16. Cell-to-Cell Transmission of HIV-1 and HIV-2 from Infected Macrophages and Dendritic Cells to CD4+ T Lymphocytes
17. Nitrobenzoates and Nitrothiobenzoates with Activity against M. tuberculosis
18. Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
19. HIV/Mtb Co-Infection: From the Amplification of Disease Pathogenesis to an “Emerging Syndemic”
20. CRISPRi-mediated characterization of novel anti-tuberculosis targets: Mycobacterial peptidoglycan modifications promote beta-lactam resistance and intracellular survival
21. INSIGHTS INTO THERAPEUTIC LIQUID MIXTURES AND FORMULATIONS TOWARDS TUBERCULOSIS THERAPY
22. Developing therapeutic strategies against Mycobacterium tuberculosis infection based on manipulation of protease inhibitors METHODOLOGY RESULTS A. siRNA-mediated gene silencing for CstC alter cathepsin activity in human macrophages infected with Mtb BACKGROUND AND AIMS
23. Liposomal delivery of repurposed antiviral drug saquinavir to macrophages as a host-directed therapy for tuberculosis
24. Liposomal Delivery of Saquinavir to Macrophages Overcomes Cathepsin Blockade by Mycobacterium tuberculosis and Helps Control the Phagosomal Replicative Niches
25. Acting on Actin During Bacterial Infection
26. Fluoroquinolone Derivatives in the Treatment of Mycobacterium tuberculosis Infection
27. Benzoic Acid Derivatives as Prodrugs for the Treatment of Tuberculosis
28. Liposomal Delivery of Newly Identified Prophage Lysins in a Pseudomonas aeruginosa Model
29. Uncovering Beta-Lactam Susceptibility Patterns in Clinical Isolates of Mycobacterium tuberculosis through Whole-Genome Sequencing
30. Spatial localization of cathepsins: Implications in immune activation and resolution during infections
31. Antimicrobial peptide-based materials: opportunities and challenges
32. Lipophilic pyrazinoic acid amide and ester prodrugs: Stability, activation and activity against M. tuberculosis
33. Modulation of Cystatin C in Human Macrophages Improves Anti-Mycobacterial Immune Responses to Mycobacterium tuberculosis Infection and Coinfection With HIV
34. Benzoic acid derivatives as prodrugs for the treatment of tuberculosis
35. Fluoroquinolone derivatives in the treatment of mycobacterium tuberculosis infection
36. Effects of omega-3 and -6 fatty acids on Mycobacterium tuberculosis in macrophages and in mice
37. Cathepsins and Their Endogenous Inhibitors in Host Defense During Mycobacterium tuberculosis and HIV Infection
38. Anti-inflammatory Effects of Phosphatidylcholine
39. Origin, Phylogeny, Variability and Epitope Conservation of SARS-CoV-2 Worldwide
40. Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
41. For Host Factors Weddings and a Koch’s Bacillus Funeral: Actin, Lipids, Phagosome Maturation and Inflammasome Activation
42. Tyrosine phosphatase MptpA of Mycobacterium tuberculosis inhibits phagocytosis and increases actin polymerization in macrophages
43. Acting on Actin During Bacterial Infection
44. Mycobacterium tuberculosis Modulates miR-106b-5p to Control Cathepsin S Expression Resulting in Higher Pathogen Survival and Poor T-Cell Activation
45. Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages
46. HIV-2 interaction with macrophages and dendritic cells
47. For Host Factors Weddings and a Koch’S Bacillus Funeral : Actin, Lipids, Phagosome Maturation and inflammasome Activation
48. Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis
49. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages
50. Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.